Acetaminophen (APAP) was determined by a simplified gas Chromatographic method, without derivatization, on a column packed with 3% OV17 on Gas Chrom Q. APAP, released enzymatically from its conjugates, was also so determined. Changes in urinary excretion patterns of APAP, its glucuronide (APAPGA) and its sulfate (APAPS) were studied as indicators of interference with metabolism of APAP. Effects of the presence of some tumors on APAP metabolism of hosts were examined, as were the effects of the following agents: phenobarbital, as a prototype of a hepatic enzyme inducer, prednisone and prednisolone, as alternate substrate inhibitors, and 5-fluorouracil (5-FU) and galactosamine, as possible modifiers of cofactors. Normal rats, Reuber H-35 hepatoma hosts and colon carcinoma hosts excreted 87.8 ± 8 percent of a 300 mg/kg dose of APAP, in the form of APAP plus APAPGA and APAPS. The presence of colon carcinoma did not alter significantly the quantities of APAP metabolites appearing in the urine of the hosts. Hepatoma hosts excreted significantly higher amounts of APAPGA, and early urine samples also contained elevated APAPS. These effects of the tumors were related to the presence of APAP conjugating enzymes in the hepatoma, and their virtual absence in the colon carcinoma tissue. The above effects on conjugations contrast with known depressive effects of tumors on mixed function oxidation pathways of hosts. Phenobarbital pretreatment (80 mg/kg, i.p., daily for 7–9 days) of Sprague-Dawley, or ACI, rats increased (3- to 4-fold) the amount of urinary APAPGA excreted in the first 3 hr after injection of APAP, and decreased (2-fold) the amount of unchanged APAP excreted. Coadministration of prednisone, or prednisolone (14 mg/kg, i.p.), with APAP caused a small but significant decrease in urinary APAPGA, which is consistent with the previously reported inhibitory effects of these steroids on APAP glucuronidation in vitro. Treatment of rats with 5-FU (120 mg/kg, i.p.) 3 hr prior to administration of APAP produced slight decreases in urinary APAPGA and APAPS. Contrary to expectations, pretreatment with galactosamine, on a schedule known to markedly reduce UDP-sugar pools, did not decrease urinary APAPGA. The results suggest that drugs which can induce hepatic glucuronyltransferase, or which can compete with APAP for the enzyme, rather than those that can alter UDP-sugar pools, are likely to have marked effects on APAP metabolism.